Evidence map›Paper›PMID 36060024›Full record

ArticleCancer diagnosis & prognosis

Variants in

Sota Kurihara, Hiroshi Matsui, Nobuaki Ohtake, Masanori Aoki, Yoshitaka Sekine, Seiji Arai, Hidekazu Koike, Kazuhiro Suzuki, Yoshiyuki Miyazawa

Abstract read
In one paragraph

Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sota KuriharaDepartment of Urology, Gunma University Graduate School of Medicine, Gunma, Japan.
Hiroshi MatsuiDepartment of Urology, Gunma University Graduate School of Medicine, Gunma, Japan.
Nobuaki OhtakeDepartment of Urology, Hidaka Hospital, Gunma, Japan.
Masanori AokiDepartment of Urology, Gunma University Graduate School of Medicine, Gunma, Japan.
Yoshitaka SekineDepartment of Urology, Gunma University Graduate School of Medicine, Gunma, Japan.
Seiji AraiDepartment of Urology, Gunma University Graduate School of Medicine, Gunma, Japan.
Hidekazu KoikeDepartment of Urology, Gunma University Graduate School of Medicine, Gunma, Japan.
Kazuhiro SuzukiDepartment of Urology, Gunma University Graduate School of Medicine, Gunma, Japan.
Yoshiyuki MiyazawaDepartment of Urology, Gunma University Graduate School of Medicine, Gunma, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimSeveral studies have reported on the relationship between HOXB13 variants and an increased prostate cancer (PC) risk. To our knowledge there are not many studies on HOXB13 mutations in Japanese patients with prostate cancer, and there many issues remain uninvestigated. We herein clarified the association between HOXB13 genetic variants and PC risk in a Japanese population. PATIENTS AND

methodsPC patients were diagnosed at the Gunma University Hospital and affiliated hospitals from 1994 to 2016. Sanger sequencing was performed on the coding regions of the HOXB13 gene in 152 familial PC (FPC) patients. Genotyping was performed on single nucleotide variants (SNVs) found in Sanger sequencing in 230 FPC patients from 152 pedigrees and 197 sporadic PC (SPC) patients and 144 controls. Allelic frequency and clinical data for each variant were studied in cases and controls.

resultsG132E and F127C were identified in FPC patients. The frequencies of G132E and F127C were significantly higher compared to the control group (p=0.039). In three families, seven PC patients shared the G132E variant, within second-to-third-degree relatives. It was not possible to clarify to pathogenicity of each SNV alone.

conclusionWe found two significant variants of the HOXB13 gene, G132E, F127C by analyzing and comparing gene samples from PC and non-PC patients. Furthermore, the HOXB13 G132E variant was found significantly increased in the FPC group.

Indexed as

familial prostate cancerHOXB13Prostate cancer

Identifiers

PMID36060024
PMCPMC9425588

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.